A biotech incubator identifying and evaluating promising pre-clinical assets in Australian universities and advancing them to clinical trials. 

ProtoAxiom has assembled a centralized management and R&D team that works closely with prolific Australian scientists and Australian universities to develop early-stage biotech assets into investable companies. The team identifies therapeutics and drug discovery platforms with best-in-class scientific and commercial potential, before in-licensing them into a central incubator that conducts IND-enabling studies and facilitates company formation. Successful platforms and assets are spun out as clinical-stage companies, bridging the significant gap between Australia’s best academic IP and biotech investors.